371 related articles for article (PubMed ID: 25828750)
61. A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer.
Son JH; Chang K; Kong TW; Paek J; Chang SJ; Ryu HS
J Obstet Gynaecol Res; 2018 Jul; 44(7):1294-1301. PubMed ID: 29683235
[TBL] [Abstract][Full Text] [Related]
62. Primary Fallopian Tube Carcinoma: A Single-Institution Experience of 101 Cases: A Retrospective Study.
Bao L; Ding Y; Cai Q; Ning Y; Hu W; Xue X; Sun H; Hua K; Zhou X; Yi X
Int J Gynecol Cancer; 2016 Mar; 26(3):424-30. PubMed ID: 26825825
[TBL] [Abstract][Full Text] [Related]
63. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.
Braicu EI; Chekerov R; Richter R; Pop C; Nassir M; Loefgren H; Stamatian F; Muallem MZ; Hall C; Fotopoulou C; Sehouli J; Pietzner K
Ann Surg Oncol; 2014 Mar; 21(3):955-62. PubMed ID: 24217786
[TBL] [Abstract][Full Text] [Related]
64. Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study.
Lim H; Bang SH; Kim Y; Cho SH; Shin W; Kim SI; Kim TH; Suh DH; Lim MC; Kim JW
BMC Cancer; 2022 Jun; 22(1):703. PubMed ID: 35761211
[TBL] [Abstract][Full Text] [Related]
65. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
66. Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
Gadducci A; Notarnicola M; Menichetti A; Lanfredini N; Fanucchi A; Cosio S
Eur J Gynaecol Oncol; 2016; 37(2):182-8. PubMed ID: 27172742
[TBL] [Abstract][Full Text] [Related]
67. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
Kuku S; Williams M; McCormack M
Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
[TBL] [Abstract][Full Text] [Related]
68. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
[TBL] [Abstract][Full Text] [Related]
69. An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.
Liang LW; Perez AR; Cangemi NA; Zhou Q; Iasonos A; Abu-Rustum N; Alektiar KM; Makker V
Int J Gynecol Cancer; 2016 Mar; 26(3):497-504. PubMed ID: 26825840
[TBL] [Abstract][Full Text] [Related]
70. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
J Gynecol Oncol; 2024 May; 35(3):e34. PubMed ID: 38216134
[TBL] [Abstract][Full Text] [Related]
71. Perioperative morbidity and mortality in octogenarians with ovarian cancer.
Walters CL; Schneider KE; Whitworth JM; Fauci JM; Smith HJ; Barnes MN; Straughn JM
Int J Gynecol Cancer; 2013 Jul; 23(6):1006-9. PubMed ID: 23714708
[TBL] [Abstract][Full Text] [Related]
72. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
Coghlan E; Meniawy TM; Munro A; Bulsara M; Stewart CJ; Tan A; Koay MHE; MaGee D; Codde J; Tan J; Salfinger SG; Mohan GR; Leung Y; Nichols CB; Cohen PA
Int J Gynecol Cancer; 2017 May; 27(4):708-713. PubMed ID: 28441251
[TBL] [Abstract][Full Text] [Related]
73. Impact of Pelvic and Para-aortic Lymphadenectomy in Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
Schwartz L; Schrot-Sanyan S; Brigand C; Baldauf JJ; Wattiez A; Akladios C
Anticancer Res; 2015 Oct; 35(10):5503-9. PubMed ID: 26408716
[TBL] [Abstract][Full Text] [Related]
74. Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
Musella A; Marchetti C; Palaia I; Perniola G; Giorgini M; Lecce F; Vertechy L; Iadarola R; De Felice F; Monti M; Muzii L; Angioli R; Panici PB
Ann Surg Oncol; 2015 Dec; 22(13):4211-6. PubMed ID: 25801357
[TBL] [Abstract][Full Text] [Related]
75. Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
Corrado G; Mancini E; Cutillo G; Baiocco E; Vici P; Sergi D; Patrizi L; Saltari M; Baffa A; Vizza E
Int J Gynecol Cancer; 2015 Sep; 25(7):1253-7. PubMed ID: 26111273
[TBL] [Abstract][Full Text] [Related]
76. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
Petrillo M; Paris I; Vizzielli G; Amadio G; Cosentino F; Salutari V; Scambia G; Fagotti A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S952-8. PubMed ID: 26036187
[TBL] [Abstract][Full Text] [Related]
77. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
[TBL] [Abstract][Full Text] [Related]
78. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
[TBL] [Abstract][Full Text] [Related]
79. Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer.
Merlo S; Besic N; Drmota E; Kovacevic N
Radiol Oncol; 2021 Aug; 55(3):341-346. PubMed ID: 33675192
[TBL] [Abstract][Full Text] [Related]
80. Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study.
Kim M; Kwon BS; Chang HK; Lee S; Chang SJ; Choi JY; Park SY; Lee M; Ryu HS; Kim YB
J Gynecol Oncol; 2019 May; 30(3):e44. PubMed ID: 30887761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
